Exactis Alpha is an independent investment research publication built to identify exceptional companies before they become widely recognized — across biotechnology, AI, and undervalued growth.
70% Biotechnology | 30% AI & Undervalued Growth
We don't publish more research.
We publish better research.
The EAM™ system evaluates each company on 100 weighted points.
Three independent analyses. One consensus score. Zero bias.
Only companies that truly earn their place get published.
Full analyses, the model portfolio, and exclusive updates.
Coverage launches September 1
Every analysis is scored by three independent analysts before it's published here. Members get the first edition on day one.
A dedicated framework for biotechnology and life sciences companies — scoring catalysts, financial strength, and scientific edge.
Learn more →A framework for exceptional companies across AI, technology, and defense & security — built for undervalued market leaders.
Learn more →